Compare ALLO & EGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | EGY |
|---|---|---|
| Founded | 2017 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 657.4M |
| IPO Year | 2018 | 1996 |
| Metric | ALLO | EGY |
|---|---|---|
| Price | $1.25 | $6.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $9.00 | ★ $10.20 |
| AVG Volume (30 Days) | ★ 5.3M | 1.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $359,272,000.00 |
| Revenue This Year | N/A | $24.31 |
| Revenue Next Year | $255.46 | $14.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $3.36 |
| 52 Week High | $4.46 | $6.72 |
| Indicator | ALLO | EGY |
|---|---|---|
| Relative Strength Index (RSI) | 25.84 | 66.71 |
| Support Level | $1.22 | $5.05 |
| Resistance Level | $2.22 | $6.67 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 25.00 | 98.35 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.